The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Cantor Fitzgerald on November 22, 2024. The analyst firm set a price target for $0.00 expecting KROS to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Cantor Fitzgerald, and Keros Therapeutics reiterated their overweight rating.

There is no last upgrade for Keros Therapeutics

There is no last downgrade for Keros Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on November 22, 2024 so you should expect the next rating to be made available sometime around November 22, 2025.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a reiterated with a price target of $0.00 to $0.00. The current price Keros Therapeutics (KROS) is trading at is $57.79, which is out of the analyst’s predicted range.